CSL Ltd. (NYSE: CSL) and its unit CSL Biotherapies on Monday said it reached a marketing and distribution deal with drug developer Merck & Co. (NYSE: MRK) for the seasonal flu vaccine Afluria.
Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.
Sign Up for our Free Stock Newsletter
Financial details of the deal were not disclosed, according to Associated Press.
Australia-based CSL makes Afluria, which is sold in both pre-filled syringes and multi-dose vials. Under the deal, CSL has a six-year, exclusive marketing and distribution deal in the U.S.
Merck will have exclusive sales and distribution rights in the U.S. beginning with the 2010-2011 flu season. CSL will retain the license.
Shares of Merck rose $1.12, or 3.6 percent, to $32.37 in afternoon trading.
Sign up for Today for our free Wall Street Grand newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Wall Street Grand
Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.
To feature a company on our web site please contact us at the email listed below.
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.
